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The  p75  neurotrophin  receptor  (p75NTR)  is  an  α-  and 
γ-secretase substrate expressed preferentially in the cholinergic 
neurons of the nucleus basalis of Meynert, the hippocampus, and 
the cerebellum of the adult brain. Mutations of the γ-secretase, 
presenilin, have been implicated in familial Alzheimer’s disease. 
Furthermore, oxidative and inflammatory injury to the cholinergic 
neurons of the nucleus basalis of Meynert and hippocampus plays 
a critical role in the pathology of Alzheimer’s disease. The intra-
cellular domain of p75NTR (p75ICD) is the α- and γ-secretase 
cleavage fragment of the holoreceptor that functions as an antiox-
idant in PC12 rat pheochromocytoma cells. Phosphorylation of 
the receptor is thought to be necessary for many of its functions, 
and two tyrosines in p75ICD have been among the function-
ally important phosphorylation sites. Site-directed mutagenesis 
was  used  to  generate  three  p75ICD  mutants  that  cannot  be 
phosphorylated at either or both tyrosines, respectively. Each of 
these mutants was expressed in p75NTR-deficient PC12 cells 
to determine the effects of blocking phosphorylation at specific 
sites  on  the  antioxidant  activity  of  p75ICD.  Interfering  with 
phosphorylation at tyrosine-337 impairs antioxidant function, 
while interfering with phosphorylation at tyrosine-366 does not, 
and may in fact impart protection from oxidant stress. Neither 
MAPK (i.e., p38, ERK1, ERK2) content nor NF-κB activation 
accounts for the differential sensitivity to oxidant stress among 
the differentially phosphorylated p75NTR cell lines. However, 
differences  in  the  time  course  of  ERK1,2  phosphorylation 
among the lines account in large measure for their differential 
oxidant sensitivity. The phosphorylation state of specific sites on 
p75ICD may modulate the resistance of neurons in Alzheimer’s 
disease-relevant brain regions to oxidant stress.
Introduction
The  p75  neurotrophin  receptor  (p75NTR)  has  been  shown 
to mediate antioxidant function in PC12 rat pheochromocytoma 
cells.1 Physiological signaling through p75NTR includes ligand 
binding and receptor dimerization, cleavage of p75NTR by α- 
and  γ-secretases,2  phosphorylation  of  the  intracellular  domain 
(p75ICD)  thereby  liberated,  binding  of  interactor  proteins  to 
phosphorylated p75ICD (with phosphorylation site dependence of 
the specific interactor that binds), and several interactor-dependent 
signaling  pathways  that  determine  whether  p75NTR  signaling 
leads to the life or death of the cell. In circumstances in which 
“life” signaling is enacted, p75ICD is as effective an antioxidant 
as full-length p75NTR.1 Thus, under physiological circumstances, 
the nature of the activity of p75NTR depends critically upon its 
phosphorylation; that is, the specific function of p75NTR in a 
given milieu is, in part, dictated by the site(s) at which phospho-
rylation occurs.3,4
The importance of cleavage of p75NTR, liberation of p75ICD, 
and the antioxidant signaling this triggers is underscored by the 
effects  of  mutation  of  the  γ-secretase,  presenilin-1,  in  familial 
Alzheimer’s disease. While p75NTR is ubiquitously expressed in 
embryonic  brain,  its  expression  is  successively  more  and  more 
restricted as the fetus matures. In the adult central nervous system, 
p75NTR  is  preferentially  expressed  in  the  cholinergic  neurons 
of  the  nucleus  basalis  of  Meynert,  the  hippocampus,  and  the 
cerebellum, loci implicated in the pathology of Alzheimer’s disease. 
Unlike  its  wildtype  counterpart,  familial  Alzheimer’s  disease 
mutant presenilin-1 is unable to cleave p75NTR and p75ICD is 
not liberated. It is hypothesized that p75NTR antioxidant activity 
is therefore not present in the neurons of patients with familial 
Alzheimer’s  disease.  Consistent  with  this  hypothesis,  reactive 
oxygen species have been hypothesized to play a role in the loss 
of cholinergic neurons in the brains of patients with Alzheimer’s 
disease.1,5,6
Coordinate  regulation  of  phosphorylation  occurs  between 
Y366 and Y337. Under baseline conditions, blocking phosphory-
lation by replacing Y366 with F results in increased spontaneous 
phosphorylation of Y337, and vice versa. However, neither mono-
phosphorylated molecule is as heavily phosphorylated after NGF 
treatment as wildtype p75NTR.3 Furthermore, phosphorylation at 
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for Y337F + Y337F/Y366F vs. aggregate of all points for wild 
type  +  Y366F  transfectants).  Cells  transfected  with  the  Y366F 
mutant are less susceptible to 6-OHDA-induced cell death than 
are  Y337F  transfectants  (p  <  0.03,  Mann-Whitney  U  test,  all 
points for Y366F vs. all points for Y337F transfectants). Double 
mutants  behave  more  like  Y337F  than  like  Y366F  mutants.   
Results obtained using the Alamar blue assay were confirmed using 
LDH release into the medium (Fig. 2C).
Assessment  of  nuclear  morphology  (20–24  h;  Fig.  3A  and 
B)  and  caspase-3  cleavage  (0  and  6  h;  Fig.  4)  after  6-OHDA   
(200 μM) treatment suggests the apoptotic nature of 6-OHDA-
induced cell death in this model and confirms the importance of 
phosphorylation  of Y337  for  the  anti-oxidant  protective  effects 
of p75ICD. Interestingly, fractional poly-ADP-ribose polymerase 
(PARP)  cleavage  at  6  and  9  h  after  addition  of  6-OHDA  to 
the  medium  of  mutant  p75ICD  transfectants  (Fig.  5)  did  not 
differ significantly from that of wild type p75ICD transfectants, 
except in the case of the 9 h determination for the double mutant   
(p  <  0.01  compared  to  wild  type,  Student’s  t-test).  Similarly,   
by 6 h after treatment with 6-OHDA, the PARP cleavage product 
is most abundant in double mutant-transfected cells.
Activation  of  signal  transductants  by  6-OHDA.  Cellular 
content  of  activated  p38  and  ERK1,2,  MAP  kinases  (MAPKs) 
Y337 is necessary (although not sufficient) 
for  c-Cbl-dependent  ubiquitination  and 
consequent internalization and degradation 
of p75NTR.4 In addition, p75NTR-medi-
ated inactivation of the inhibitor of neurite 
outgrowth,  Rho,  requires  phosphoryla-
tion of Y366 within the death domain of 
p75NTR. This residue lies between helices 
2 and 3 and it is hypothesized that phos-
phorylation at his locus controls spacing 
between helices 2 and 3 and helices 4 and 
5.3 Thus, phosphorylation of p75NTR is 
one of the arbiters of the function of this 
receptor.
We  sought  to  examine  the  effects  of 
phosphorylation  of  Y337  and  Y366  on 
the  antioxidant  effects  of  p75ICD  in 
PC12 cells. Using site-directed mutagen-
esis,  we  transfected  p75NTR-negative 
PC12 cells1,7 with wildtype and each of 
three mutant (Y337F, Y366F, and Y337F/
Y366F,  respectively)  p75ICD  expression 
constructs. Interfering with phosphoryla-
tion at Y337 impairs antioxidant function, 
while interfering with phosphorylation at 
Y366  enhances  neuroprotection.  These 
findings  suggest  potential  therapeutic 
targets for enhancing (as one might want to 
do  in  combating  neural  tumors)  or 
diminishing (as one might want to do in 
preventing  Alzheimer’s  disease)  the  cyto-
toxic effects of reactive oxygen species in 
the nervous system.
Results
Expression  and  phosphorylation  of  p75ICD  in  transfected 
p75NTR-deficient cells. Western blot analysis demonstrates that 
p75ICD is expressed in all of the transfectants except the mock 
transfectants (Fig. 1A and B). Although the relative intensity of 
the bands varied from blot to blot, on repeated assessment, the 
p75ICD  protein  content  (n  =  3  independent  blots)  does  not 
differ significantly from transfectant to transfectant (p > 0.05 for 
all  paired  comparisons;  Student’s  t-test,  Bonferroni  correction). 
Maintenance of p75ICD-transfected PC12 cells in the presence of 
the tyrosine phosphorylase inhibitor, sodium orthovanadate results 
in detection of phosphorylated Y (pY) in each of the immunopre-
cipitated p75ICD mutants (Fig. 1C).
Cell  survival  after  treatment  with  6-OHDA.  As  we  have   
previously  reported,1  transfection  of  p75NTR-deficient  PC12   
cells with wildtype p75ICD protects them from 6-OHDA-induced 
cell death (Fig. 2A; p < 0.04, Mann-Whitney U test, aggregate of 
all points for wild type p75ICD vs. aggregate of all points for 
mock  transfectants).  Cells  transfected  with  the  Y337F  mutant 
or Y337F/Y366F double mutant, respectively, are more sensitive 
to  6-OHDA  than  are  wildtype  or Y366F  mutant  transfectants   
(Fig. 2B; p < 0.05, Mann-Whitney U test, aggregate of all points 
Figure 1. Optical density (OD) of the p75ICD bands on Western blotting of homogenates of p75NTR-
deficient PC12 cells transfected with empty plasmid (mock) or wildtype (WT), Y337F, Y366F, of 
Y337F/Y366F double mutant (dm) p75ICD, respectively, normalized to the OD of the β-actin bands 
on the same gel. Results shown are the mean ± SEM of three independent determinations. A single 
representative blot is shown below the graph. Note that our previous publication includes the com-
parison of transfected full length p75NTR, p75ICD, and its relative, p75ΔECD.1 The antibody used 
for that study and for the present one is an antibody to the full length p75NTR. The p75-negative cells 
have previously been demonstrated to be holo-p75-negative.6,7Phosphorylation of p75NTR and neuroprotection
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p-ERK/Total ERK. Resting p-p38 is lowest in double mutant- and 
Y366F-transfected  cells.  Resting  p-IκB-α  content  is  highest  in 
Y366F cells (Fig. 7).
Discussion
The  neurotrophin  receptor,  p75NTR,  protects  PC12  pheo-
chromocytoma cells from oxidant stress.1 p75ICD, a cytoplasmic 
fragment  liberated  upon  ligand  binding  to  the  extracellular 
domain of p75NTR, can substitute for the holoreceptor in this 
regard. Previous studies have demonstrated that p75ICD phos-
phorylation plays a role in its activity and in determining which   
of  several  p75NTR-triggered  signaling  pathways  is  activated.3,4   
implicated in p75NTR signaling, and of the activation product of 
NF-κB, IκB-α, were examined in untreated wildtype and mutant 
p75NTR cells grown in serum- (i.e., NGF-) containing medium. 
Total  ERK1,2  content  is  similar  for  all  four  cell  lines.  Resting 
p-ERK1,2 content is highest in wildtype cells and lowest in Y366F 
cells (Fig. 6). The time course of ERK1,2 activation differs among 
the  transfectants.  Mock-  and  Y337F-transfected  cells  exhibit 
biphasic enhancement of p-ERK/Total ERK in the 4 h following 
6-OHDA treatment, with return to baseline levels between phases. 
By the 4 h and 1 h time points, respectively, wildtype and double 
mutant-transfected cells exhibit a monophasic decrease in p-ERK/
Total ERK, while Y366F cells exhibit a monophasic increase in 
Figure 2. Concentration-response curves (Alamar blue and LDH release determinations of relative cell death; see Experimental Procedure) for p75NTR-
deficient PC12 cell p75ICD transfectants treated with 6-OHDA. (A) Mock-transfected cells are compared by Alamar blue assay with cells transfected 
with wildtype (WT) p75ICD; (B) Cells transfected with WT p75ICD are compared by Alamar blue assay with cells transfected, respectively, with each 
of the mutant p75ICD constructs. DM = Y337F/Y366F p75ICD. Each point represents the mean ± SEM of nine independent determinations. (C) Cells 
transfected with WT p75ICD are compared by LDH release assay with cells transfected, respectively, with each of the mutant p75ICD constructs.   
DM = Y337F/Y366F p75ICD. Each point represents the mean ± SEM of 9 independent determinations. For (A, B and C), individual time point results 
differ from that obtained for WT p75ICD cells with p < 0.05 (*); p < 0.01 (**); or p < 0.001 (***) as determined by Student’s t test.www.landesbioscience.com Oxidative Medicine and Cellular Longevity 241
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We  have  used  site-directed  mutagenesis  to  generate  single  and 
double  mutants  of  p75ICD  at  Y337  and  Y366.  The  mutants 
involve substitution of F for Y and therefore cannot be phospho-
rylated at the mutated position. These studies demonstrate that 
p75NTR-negative PC12 cells transfected with wildtype or Y366F 
p75ICD are more resistant to oxidative stress than cells that are 
transfected with Y337F or Y337F/Y366F double mutant p75ICD. 
As both wildtype and Y366F p75ICD mutant can be phosphory-
lated on Y337 and both Y337F and Y337F/Y366F cannot, our 
results suggest that phosphorylation of Y337 of p75ICD plays an 
essential role in the p75ICD-mediated protection of PC12 cells 
from cell death due to oxidant stress.
Interestingly, as phosphorylation of Y337 is essential for ubiq-
uitination  of  p75NTR  prior  to  its  degradation,4  protein  levels 
of  the  p75ICD Y366F  mutant  might  be  expected  to  be  lower 
than that of the other mutants. On the other hand, in the Y337F 
mutant, none of Y337 is phosphorylated and thus the p75ICD 
protein level might be predicted to be highest compared to the 
other three mutants. However, on average, there were no signifi-
cant differences in p75ICD content among the cells expressing the 
four different p75ICD sequences (Fig. 1).
Phosphorylation of p75NTR has been hypothesized to involve 
transfer of a phosphate from MAPK p38 to p75NTR; there is 
evidence that p38 can interact directly with the fifth and sixth 
alpha  helices  of  p75NTR  in  the  C-terminal  death  domain.8 
Interestingly, Y366 is located between helix 2 and 3 of p75ICD 
in the open pocket for p38. However, our studies demonstrate 
no correlation between protective activity of phosphorylation site 
mutants of p75ICD and cellular content of phosphorylated p38 
(Fig. 7). Of interest in this regard, members of the MAPK family, 
including  p38  and  ERK1,2,  have  been  shown,  like  p75NTR, 
to be pro- or anti-apoptotic in neuronal systems and to be crit-
ical  in  oxidant-induced  apoptosis  in  hepatocytes  in  culture.9,10 
Furthermore,  p38  activation  is  critical  for  6-OHDA-induced 
Figure 3. See previous page. Incidence of morphological apoptosis in p75NTR-deficient PC12 cells transfected with wildtype (WT), Y337F, Y366F,   
or Y337F/Y366F (DM) p75ICD, respectively, treated with 6-OHDA. Representative fields are shown under (A): phase contrast microscopy (10x) 
and after Hoechst staining followed by fluorescence microscopy (10x), for cells treated with 200 μM 6-OHDA. Manual counts of apoptotic and non-
apoptotic cells were performed on six fields under fluorescence microscopy for each of the four transfectants. In (B), fields (a and b) from (A) are shown 
at 200x magnification to demonstrate nuclear condensation and fragmentation and, in the graph, the mean ± SEM of the manual cell counts is shown   
(***p < 0.001, Student’s t test).
Figure 4. Activated caspase-3 6 h after treatment with 6-OHDA (200 μM) in p75NTR-deficient PC12 cells transfected with wiltype (WT), Y337F, Y366F, 
or Y337F/Y366F (DM) p75ICD, respectively. In the graph, densitometric values for each transfectant before treatment (0 h) are subtracted from values 
at 6 h after treatment to obtain the values plotted (mean ± SEM; **p < 0.01, *p < 0.05 relative to WT p75ICD transfectant, Student’s t-test).www.landesbioscience.com Oxidative Medicine and Cellular Longevity 243
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apoptosis  in  the  CNS-derived  tyrosine  hydroxylase  expressing   
B65 cell line.11 This complex relationship between activation of 
any of the MAPKs and the life or death of the cell may account 
for our observation, shown in Figures 6 and 7, that mutants with 
similar  susceptibility  to  6-OHDA-induced  death  have  different 
levels at baseline of activation of the MAPKs p38 and ERK 1,2 
relative to wildtype p75ICD cells.
The time course of ERK activation is of particular interest in 
light of the observation of Luo and DeFranco12 that activation 
of ERK in response to oxidative stress is biphasic and consists of 
an early, brief, compensatory, protective phase followed by a late, 
prolonged,  cell-injurious  phase.  Mock-  and  Y337F-transfected 
cells  demonstrate  both  of  these  phases  of  ERK  activation  and 
are  most  susceptible  to  6-OHDA-induced  death.  Cells  trans-
fected with wildtype p75NTR have high levels of activated ERK 
at baseline and demonstrate a paradoxical decrease in activated 
ERK at the usual time of the injurious phase of ERK activation. 
This is perhaps responsible for the protection of these cells from 
6-OHDA-induced death. Y366F- and double mutant-transfected 
cells exhibit ERK activation time courses that do not fit a conven-
tional pattern. Y366F-transfected cells demonstrate early increased 
ERK activation that increases in magnitude with time, without 
return to baseline. Given the resistance of these cells to 6-OHDA-
induced  cell  death,  it  is  tempting  to  speculate  that  the  return 
to baseline between ERK activation phases is necessary for the 
transition of p-ERK from protective to injurious. Double mutant-
transfected cells demonstrate high baseline levels of ERK activation 
and early-onset progressively decreasing ERK activation.
Phosphorylation  of  p75NTR  has  been  shown  to  enhance 
NF-κB activation.8,13,14 Our studies demonstrate that activation 
of NF-κB is greatest in the Y366F mutant (Fig. 7), implying that 
phosphorylation  of  Y366  may  inhibit  and  phosphorylation  of 
Y337 may enhance activation of NF-κB.
Several  markers  of  apoptosis  were  examined  in  the  present 
study. Exposure to 6-OHDA results in nuclear margination and 
fragmentation (Fig. 3A and B) and cleavage of caspase-3 (Fig. 4) 
and PARP (Fig. 5) in all transfectants. It is interesting that the 
fractional caspase-3 activation and fractional PARP cleavage for 
each  transfectant  do  not  correlate  absolutely  and  quantitatively 
with one another or with resistance to oxidant stress. There are 
two possible, non-mutually exclusive explanations for this. First, 
it likely that cell death in this model, as in others,15 occurs by a 
combination of apoptosis and necrosis and the relative incidence of 
these two mechanisms of cell death differ among the transfectants. 
Second, while useful for the binary decision of whether cells in a 
given model die by apoptosis or necrosis, Western blotting does 
not allow for precise kinetic or quantitative comparisons of PARP 
cleavage from cell line to cell line or tissue to tissue.16
The significance of the differing roles in the anti-oxidant effects 
of p75ICD of phosphorylation of p75ICD at Y337 and Y366, 
Figure 5. Ratio of PARP cleavage product to total PARP (A) and PARP cleavage product alone (B) determined by measuring the optical density of bands 
for intact and cleaved PARP on gel electrophoresis of homogenates of 6-OHDA-treated (200 μM), p75ICD-transfected, p75NTR-deficient PC12 cells. 
Results plotted represent the mean ± SEM of three independent determinations. A single representative set of Western blot results is shown below the 
graph. (**p < 0.01, Student’s t test)Phosphorylation of p75NTR and neuroprotection
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respectively, for Alzheimer’s disease is not clear. Oxidative injury   
to  cholinergic  central  neurons  plays  a  role  in  this  disorder.   
In familial Alzheimer’s disease, mutation of presenilin, a γ-secretase 
for which p75NTR is a substrate, prevents release of p75ICD. 
However, sporadic Alzheimer’s disease, the more common of the 
two, does not involve mutation of presenilin. Our studies suggest 
that altered phosphorylation of p75ICD could also result in the 
enhanced likelihood of apoptotic death of neurons subjected to 
oxidative stress.
Experimental Procedure
Chemicals.  Ascorbic  acid  and  6-OHDA  were  obtained   
from Sigma Aldrich, Inc. (St. Louis, MO). To prevent extracellular 
oxidation of 6-OHDA, solutions for use in cell culture experiments 
were made up in iced saline containing 250 μM ascorbic acid with 
a minimum of agitation immediately before use. Ascorbic acid 
does  not  penetrate  the  cell  membrane,  and  therefore  does  not   
alter  the  intracellular  effects  of  6-OHDA.  Catecholamine 
transporter-mediated  uptake  of  6-OHDA  by  and  intracellular 
generation  of  reactive  oxygen  species  in  PC12  cells  have  been 
previously demonstrated.17,18
Cell  cultures.  Polyclonal  p75NTR-deficient  PC12  cells  have 
been  described  in  our  previous  publications.5,7  Briefly,  as  a 
population,  native  PC12  cells  are  p75NTR-  and TrkA-positive 
(~40,000  p75NTR  receptors  per  cell  and  ~400 TrkA  receptors 
per cell). p75NTR-deficient (0 p75NTR receptors per cell and 
~400 TrkA receptors per cell) PC12 cells were selected and assayed 
for receptor content initially and again every several passages as 
follows.  Subclones  of  PC12  cells  were  selected  on  the  basis  of 
absent cell-surface p75NTR receptors as determined by FACScan 
analysis using the monoclonal antibody mAbMC192, a ligand of 
the extracellular domain of p75NTR.19,20 Subclones were then 
grown and examined by RT-PCR for mRNA for the p75NTR 
receptor. Studies were performed on pooled subclones, comprising 
a polyclonal, p75NTR-negative population of PC12 cells.
The  p75NTR-deficient  PC12  cells  were  maintained  in 
Dulbecco’s modified Eagle’s medium (Mediatech, Inc., Manassas, 
VA) supplemented with 10% horse serum and 5% fetal bovine 
serum (Atlanta Biologicals, Norcross, GA) and 1.1% penicillin/
streptomycin (Invitrogen, Carlsbad, CA). The cells were fed twice 
weekly.
Site-directed mutagenesis. Site-directed mutagenesis was carried 
out following the protocol from Stratagene (La Jolla, CA) for the 
QuickChange  Site-Directed  Mutagenesis  Kit. The  template  for 
PCR was the p75ICD gene sequence cloned into the pcDNA3.1 
TOPO V5 His plasmid.1 Primers were designed to change Y to F 
Figure 6. Phosphorylation of ERK1,2 in p75ICD mutants. (A) A representative Western blot of three performed is shown. (B) Densitometric results for 
(p-ERK1 + p-ERK2)/(ERK1 + ERK2) derived from the blot shown in (A), above. *Direction and relative magnitude of difference from t = 0 min reproduced 
in all three Western blots.www.landesbioscience.com Oxidative Medicine and Cellular Longevity 245
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by changing the A of the Y codon (TAC) to T giving the F codon 
(TTC)  for  both  Y337  and  Y366.  Primers  were  constructed  so 
that, in each case, the changed nucleotide was the fifth nucleotide 
from the 5’ end. We used forward CTCTTCAGTAGCCTGC- 
CCCTGACC and reverse ACTGAAGAGGTTGCCATCACCC- 
TTG  primers  in  PCR  to  make  Y337F  mutants  and  forward 
GGTTTCCAGCCTGAACATATAGACTCC and reverse CTG- 
GAAACCCAGCTCGCCTGCCAG  primers  to  make  Y366F 
mutant. PCR was carried out at 72°C for extension for 30 cycles 
of 30 sec each. After Dpn I cleavage, the PCR product was used 
for transformation and positive colonies were selected and verified 
by DNA sequencing. The Y337F/Y366F double mutant was made 
using Y337F as a template and the Y366F mutant as primers in 
PCR.
Transfection.  After  culture  in  complete  medium  for  several 
days,  the  p75NTR-deficient  PC12  cells  were  transfected  with 
plasmids containing either Y337F or Y366F or Y337F/Y366F by 
electroporation using Amaxa Nucleofector Kit V program U29. 
After 2 days in regular medium, 500 μg/ml of G418 was added 
to the medium to select stable positive colonies. Thereafter, the 
maintenance medium contained 20 μg/ml G418.
Treatment  of  cells  with  6-OHDA.  PC12  cells  were  seeded 
on 96-well plates at between 12,000 and 20,000 cells per well 
and incubated at 37°C overnight. The next day, the cells were 
treated with 6-OHDA in saline containing 250 μM ascorbic acid.   
In the Hoechst staining and PARP cleavage experiments, the final 
concentration of 6-OHDA was 500 μM. 6-OHDA remained in 
the medium until the cells were ready for fixation and staining, 
or until performance of the Alamar blue assay or SDS PAGE for 
Western blotting.
Western blotting. For Western blot analysis for p75ICD and 
intact and cleaved PARP, p75NTR-deficient PC12 cells were lysed 
in RIPA buffer (10 mM Tris, pH 8, 150 mM NaCl, 0.1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 4 mg/ml 
aprotinin, 1 mM sodium orthovanadate) for at least 30 min on ice. 
Subsequently, the protein concentration was estimated in triplicate 
samples using the Bio-Rad protein assay (Bio-Rad Laboratories, 
Hercules, CA, USA) with bovine serum albumin as a standard. 
Equivalent  amounts  of  protein-containing  lysates  were  loaded 
onto each lane and electrophoresed in 10% SDS-polyacrylamide 
gel, followed by blotting onto a nitrocellulose membrane (Bio-Rad 
Laboratories).  After  blotting,  non-specific  binding  was  blocked 
with 5% non-fat dry milk in PBS for 1 h. The membrane was 
then incubated for 2 h at room temperature with anti-p75NTR 
antibody  (Promega,  Madison,  WI)  or  overnight  at  4°C  with 
anti-PARP  antibody  (Cell  Signaling,  Danvers,  MA),  anti-phos-
photyrosine  antibody  (phosphotyrosine  clone  2C8  monoclonal 
antibody; Nano Tools, San Diego, CA), or anti-activated caspase 
3 antibody (catalog #9661; Cell Signaling, Danvers, MA) diluted 
1: 1000 into 5% non-fat dry milk in PBS. The membrane was 
then washed with PBS, and incubated with secondary horseradish 
peroxidase-conjugated anti-rabbit IgG antibody or anti-mouse IgG 
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h. The 
membrane was finally washed and developed with Western blotting 
chemiluminescence luminol reagent (Santa Cruz Biotechnology) 
following the manufacturer’s instructions.
Cell and apoptotic fraction counts. Alamar blue assay. After 
cells  were  treated  with  6-OHDA  for  24  h,  the  medium  was 
removed and 100 μl new medium containing a 1:10 dilution of 
Alamar blue (Serotec, Oxford, UK) was added to each well and the 
plate was incubated at 37°C for 1 h. Alamar blue fluorescence was 
determined at an excitation wavelength of 530 nm and an emission 
wavelength of 590 nm using a plate reader.
Hoechst dye staining. PC12 cells were seeded at 20,000 per 
well onto a 96-well plate at day 0 and treated with 6-OHDA on   
Day 1. On Day 2, the 6-OHDA-containing medium was removed 
and the cells were gently washed 3 times with PBS. After adding   
50 μl Hoechst dye (20 μg/ml) in 4% paraformaldehyde-PBS to 
each well, the plate was incubated for 30 min at room temperature.   
The Hoechst dye was removed and the wells were washed three 
times with PBS. The cells were kept in fresh PBS for fluorescent 
microscopic examination. 
LDH  cytotoxicity  detection  assay.  PC12  cells  were  seeded 
onto 96-well plates on Day 1. On Day 2, when cells were about 
70–80% confluent, they were treated with 6-OHDA at a final 
concentration of 0, 100, 200, 300, 400 or 500 μM for 3 h. Cells 
were  then  placed  in  regular  medium.  After  24  h,  LDH  liber-
ated into the overlying medium was quantified using an LDH 
Detection Kit (catalogue #04 744 926 001; Roche, Mannheim, 
Germany) according to the manufacturer’s instructions. 
Sodium orthovanadate treatment of PC12 cells. Mock- and 
wild type and mutant p75ICD-transfected PC12 cells were seeded 
onto 10 cm culture dishes and grown in DMEM containing 5% 
FBS and 10% horse serum until they attained 80% confluence. 
Cells  were  then  washed  twice  with  PBS  at  room  temperature. 
Equal  columes  of  sodium  orthovanadate  (200  mM)  and  8% 
hydrogen peroxide were mixed and immediately pipetted (10 μl) 
into 10 ml warm PBS and added to each dish. The treated cells 
were incubated at 37°C for 5 min. After rinsing with ice cold PBS, 
the cells were collected using cell scrapers and stored at -80°C 
until they were ready for Western blot or immunoprecipitation 
analysis.
Immunoprecipitation. To an aliquot containing 600 μg protein 
and  taken  from  each  cell  lysate  was  added  RIPA  buffer  with 
protease  inhibitor  and  phosphatase  inhibitor  cocktails  (Sigma 
8340, 2850) to make a total volume of 700 μl. Protein A agarose 
beads and normal rabbit IgG (Santa Cruz) were then added and 
the tubes were incubated in a rotor in the cold room for at least   
3 h. The beads were then spun down at 4000 g in the cold room 
and 10 μg anti-human p75 rabbit pAb (Promega G323A) was 
Figure  7.  Phosphorylation  of  the  MAPK,  p38,  and  of  IκB-α  examined 
in p75ICD mutants. A representative Western blot of three performed is 
shown.Phosphorylation of p75NTR and neuroprotection
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added  to  the  supernatant  and  incubated  overnight  in  the  cold 
room. The next day, Protein A agarose beads were added again and 
tubes were incubated in a rotor for at least 3 h in the cold room. 
The beads were then spun down and washed with RIPA buffer at 
least four times and then dissolved into 50 μl SDS sample loading 
buffer for SDS electrophoresis. 
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